v3.26.1
Summary of Significant Accounting Policies - Schedule of Percentage of Revenue and Accounts Receivables from Customers (Details) - Customer Concentration Risk
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Revenue | Merck & Co., Inc.          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage 37.00% 11.00% 30.00%    
Revenue | VA MVP          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage 13.00% 19.00% 15.00% 20.00%  
Revenue | ModernaTX, Inc.          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage 12.00% 29.00% 14.00% 28.00%  
Revenue | Natera Inc.          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage   13.00%   13.00%  
Accounts Receivable | Merck & Co., Inc.          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage     49.00%   12.00%
Accounts Receivable | US Department of Veterans Affairs          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage         24.00%
Accounts Receivable | AstraZeneca UK Limited          
Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage         10.00%